Princeton Global Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Princeton Global Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150	Closed	-$26K	–	520
2020 Q4	$26K	Hold	150	–	–	0.01%	304
2020 Q3	$21K	Hold	150	–	–	0.01%	287
2020 Q2	$24K	Hold	150	–	–	0.01%	325
2020 Q1	$15K	Hold	150	–	–	0.01%	342
2019 Q4	$19	Hold	150	–	–	0.01%	341
2019 Q3	$12K	Hold	150	–	–	0.01%	296
2019 Q2	$23K	Hold	150	–	–	0.01%	278
2019 Q1	$17K	Buy	+150	New	+$19.3K	0.01%	265

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Princeton Global Asset Management's SRPT Position: Q1 2021 in Review

Princeton Global Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 150 shares — an estimated $26K sold.

Princeton Global Asset Management first reported a position in SRPT in Q1 2019 and held it in 8 quarters. The position peaked at $26K in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Princeton Global Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Princeton Global Asset Management sold 150 Sarepta Therapeutics shares in Q1 2021, an estimated $26K.
Princeton Global Asset Management first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 8 quarters.
Princeton Global Asset Management's Sarepta Therapeutics position peaked at $26K in Q4 2020.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Princeton Global Asset Management's 13F filing for Q1 2021, filed 11 May 2021.